The United States Food and Drug Administration (FDA) has approved multiple PARP inhibitors for the treatment of BRCA mutation-positive breast cancer (Mccann and Hurvitz, 2018) and advanced ovarian cancer (Colombo et al., 2018). Here, PARP1 is linked to breast carcinoma.